Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.

Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC.

Crit Care Med. 2014 Jul;42(7):1714-21. doi: 10.1097/CCM.0000000000000325.

2.

Paving a new road for generating evidence-based care in sepsis*.

Annane D.

Crit Care Med. 2014 Jul;42(7):1743-4. doi: 10.1097/CCM.0000000000000385. No abstract available.

PMID:
24933058
3.

New and emerging therapies for sepsis.

Healy DP.

Ann Pharmacother. 2002 Apr;36(4):648-54. Review.

PMID:
11918516
4.

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.

PMID:
17973539
5.

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

Crit Care. 2008;12(5):R117. doi: 10.1186/cc7011. Epub 2008 Sep 11.

6.

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.

McCoy C, Matthews SJ.

Clin Ther. 2003 Feb;25(2):396-421. Review.

PMID:
12749504
7.

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.

Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A.

Crit Care. 2005;9(6):R607-22. Epub 2005 Sep 22. Review.

8.

Addressing the global burden of sepsis: importance of a systems-based approach.

Dobson GP.

Crit Care Med. 2014 Dec;42(12):e797-8. doi: 10.1097/CCM.0000000000000595. No abstract available.

PMID:
25402302
9.

The authors reply.

Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC.

Crit Care Med. 2014 Dec;42(12):e798-9. doi: 10.1097/CCM.0000000000000681. No abstract available.

PMID:
25402303
10.

Clinical impact of novel anticoagulation strategies in sepsis.

Opal SM.

Curr Opin Crit Care. 2001 Oct;7(5):347-53. Review.

PMID:
11805532
11.
12.

Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.

Kanji S, Devlin JW, Piekos KA, Racine E.

Pharmacotherapy. 2001 Nov;21(11):1389-402. Review.

PMID:
11714212
13.

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. doi: 10.1186/cc6156. Review.

14.

Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).

Rudis MI, Fish DN.

Pharmacotherapy. 2002 Dec;22(12 Pt 2):182S-195S. Review.

PMID:
12492225
15.

Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Martí-Carvajal AJ, Solà I, Gluud C, Lathyris D, Cardona AF.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD004388. doi: 10.1002/14651858.CD004388.pub6. Review.

PMID:
23235609
16.

Human recombinant activated protein C for severe sepsis.

Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004388. doi: 10.1002/14651858.CD004388.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD004388.

PMID:
22419295
17.

[Should patients with severe sepsis be treated with activated protein C?].

Laake JH, Bergmann JB, Riddervold F, Bjørneklett A, Aukrust P, Frøland SS.

Tidsskr Nor Laegeforen. 2004 Mar 18;124(6):782-4. Review. Norwegian.

18.
19.

Recombinant human activated protein C in severe sepsis.

Mann HJ.

Am J Health Syst Pharm. 2002 Feb 15;59 Suppl 1:S19-23. Review.

PMID:
11885409
20.

Supplemental Content

Support Center